Skip to main navigation
Skip Navigation
Landos Biopharma
  • - Landos - Corp Menu

  • About Us
    • Our Company
      • Management Team
      • Board of Directors
      • Clinical Advisory Board
    • Contact Us
  • Product Candidates
    • NX-13
    • Preclinical Candidates
    • Clinical Trials
  • Science
    • LANCE Precision Medicine Platform
    • Immunometabolic Pathways
    • Publications
  • Investors/Media
    • Investor/Media Home
    • Press Releases
    • Events & Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investors/Media FAQs
  • Careers
    • Why Landos?
    • Open Positions
Identifying novel pathways at the interface of immunity and metabolism

Press Releases

2/28/23
Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder
1/11/23
Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization
1/5/23
Landos Biopharma Provides Comprehensive Update on Clinical Development Plans
1/5/23
Landos Biopharma Announces $16.7 Million Private Placement Financing

Investors/Media

Investor Relations

  • Investor/Media Home
  • Press Releases
  • Events & Presentations
  • Analyst Coverage
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investors/Media FAQs

- Landos - Investor Tools

  • Print Page
  • RSS Feeds
  • Email Alerts
Landos Biopharma, Inc.
PO Box 11239
Blacksburg, VA 24062
info@landosbiopharma.com
(540) 218-2232

- Landos - Footer Menu

  • Site Map
  • Terms of Use
  • Privacy Policy

©2023 Landos Biopharma All Rights Reserved.